MARKET RESEARCH TREND

OVERVIEW OF THE PHARMACEUTICAL MARKET IN IRAQ Years of underinvestment have taken their toll on the Iraqi healthcare market, as have international sanctions and deterioration of healthcare infrastructure due to war. Still an unpopular figure on the international market, Iraq\'s trade partners are few and far between - although Iraq does have a strong bargaining chip: its oil resources. Healthcare facilities are gradually improving, with plans for new hospitals such as two specialist hospitals planned in partnership with Iran\'sRed Crescent organisation. But access to funding is limited, import and exports are restricted, and the country has a severe shortage of trained medical professionals. As such, it is of little surprise that there are few distinctions in the market between OTC and prescription drugs, and counterfeit medicines are rife. Headline Expenditure Projections Pharmaceuticals : IQD1,239bn (US$1.06mn) in 2011 to IQD1,476bn (US$1.26bn) in 2012; +

THE PHARMACEUTICAL MARKET OF LITHUANIA - REVIEW We continue to hold our subdued outlook for the Lithuanian pharmaceuticals market during the next few years, on account of the changing economic and demographic situation. We expect limited low single digit growth in 2012 , with the market expected to increase by a local currency margin of 2.5% year-on-year (y-o-y) to reach LTL1.6 8 bn (US$6 18 mn) in 2012 at consumer prices. However, in US dollar terms, the market \' s value will shrink by 6.3%, in dicating the challenges facing companies operating in the market . Headline Expenditure Projections Pharmaceuticals: LTL1.64bn (US$659mn) in 2011 to LTL1.68bn (US$618mn) in 2012; +2.5% in local currency terms and -6.3% in US dollar terms. Forecastslightly upfrom Q4 12on account of new macroeconomic data. Healthcare: LTL6.99bn (US$2.81bn) in 2011 to LTL7.29bn (US$2.68bn) in 2012; +4.3% in local currency terms and -4.7% in US dollar terms. Forecast slightly up fro

OVERVIEW OF THE PHARMACEUTICAL MARKET IN SAUDI ARABIA Saudi Arabia\' s transition to an increasingly privatised and comprehensive healthcare system will drive the demand for both patented and generic drugs . The country is investing heavily in healthcare infrastructure and we expect this will be borne out in double-digit growth forecasts across our three headline indicators. Headline Expenditure Projections Pharmaceuticals: SAR16.70bn (US$4.46bn) in 2011 to SAR18.95bn (US$5.06bn) in 2012; +13.5% in local currency and US dollar terms. Forecastbroadly unchanged from Q3 12. Healthcare: SAR78.63bn (US$21.00bn) in 2011 to SAR91.20bn (US$24.35bn) in 2012; +16.0% in local currency and US dollar terms. Forecast broadly unchanged from Q3 12. Medicaldevices: SAR5.54bn (US$1.48bn) in 2011 to SAR6.53bn (US$1.74bn) in 2012; +17.8% in local currency and US dollar terms. Forecastunchanged from Q3 12. To Browse a Full Report with TOC @ http://www.resear